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Zsófia Hegedüs, ‡a Fruzsina Hóbor, bc Deborah K. Shoemark, e
Sergio Celis, a Lu-Yun Lian, d Chi H. Trinh, bc Richard B. Sessions, e
Thomas A. Edwards bc and Andrew J. Wilson *ab
b-Strand mediated protein–protein interactions (PPIs) represent underexploited targets for chemical probe
development despite representing a significant proportion of known and therapeutically relevant PPI
targets. b-Strand mimicry is challenging given that both amino acid side-chains and backbone
hydrogen-bonds are typically required for molecular recognition, yet these are oriented along
perpendicular vectors. This paper describes an alternative approach, using GKAP/SHANK1 PDZ as
a model and dynamic ligation screening to identify small-molecule replacements for tranches of peptide
sequence. A peptide truncation of GKAP functionalized at the N- and C-termini with acylhydrazone
groups was used as an anchor. Reversible acylhydrazone bond exchange with a library of aldehyde
fragments in the presence of the protein as template and in situ screening using a fluorescence
anisotropy (FA) assay identified peptide hybrid hits with comparable affinity to the GKAP peptide binding
sequence. Identified hits were validated using FA, ITC, NMR and X-ray crystallography to confirm
selective inhibition of the target PDZ-mediated PPI and mode of binding. These analyses together with
molecular dynamics simulations demonstrated the ligands make transient interactions with an
unoccupied basic patch through electrostatic interactions, establishing proof-of-concept that this
unbiased approach to ligand discovery represents a powerful addition to the armory of tools that can be
used to identify PPI modulators.Introduction
Protein–protein interactions (PPIs) play an essential role in the
majority of biological processes and therefore represent arbiters
of health and disease.1,2 Chemical probes for PPIs offer
tremendous opportunities to understand PPIs and therefore
biological mechanisms, whilst providing starting points forodhouse Lane, Leeds LS2 9JT, UK. E-mail:
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the Royal Society of Chemistrydrug-discovery.3 Conventional ligand discovery methods (e.g.
fragment screening and elaboration) have delivered PPI
modulators for a number of targets4–6 leading to clinically
approved drugs such as Venetoclax (ABT-199).7 However,
despite the enormous opportunity offered by PPIs, methods to
identify modulators of PPIs remain underdeveloped. Peptide
interacting motifs represent promising templates for design
given they are likely to mediate a signicant proportion of PPIs;8
however, selecting the most appropriate scaffold to inhibit
a specic PPI is highly dependent on the properties of the target
interaction and varies in difficulty across PPI classes.9,10 There
has been considerable success in developing generic
approaches to mimic the a-helix and inhibit a-helix mediated
PPIs (e.g. using peptides, constrained peptides and peptidomi-
metics), but less so for other PPI topographies.11,12 In particular,
b-strand/b-sheet mediated PPIs exhibit a more complex topog-
raphy and have proven more challenging; these interfaces are
shallower and more elongated with backbone hydrogen
bonding contributing signicantly to the binding energy.13,14
Scaffolds that mimic b-strands/b-sheets15–20 have hitherto seen
limited application21–23 in PPI inhibitor discovery.24–29
In this work, we take a novel approach to b-strand mimicry
whereby a truncated protein-interacting motif is combined withChem. Sci.
Fig. 1 (a) Design and screening strategy for identification of hybrid
inhibitors. Schematic depicting the design strategy for identification of
small molecule-peptide hybrids using a truncated anchor peptide
derived from a known interaction partner of the protein target, and (b)
Schematic depicting fluorescence anisotropy (r) competition assay-
based screen for the identification of hit compounds that compete
with a fluorescently labelled ligand at the target binding site.
Fig. 2 Design principles for the anchor peptides based on the GKAP/
SHANK1 PDZ interaction. (a) General reaction scheme for acylhy-
drazone exchange using peptide hydrazones and aldehydes in the
presence of 10 mM aniline at pH 6.5. Anchor peptides generated from
the GKAP sequence (cyan) based on its binding properties to SHANK1
PDZ (green, 1Q3P), truncated either from (b) the C terminus or (c)
the N terminus. Residues outlined in white indicate the truncated
























































































View Article Onlinea small-molecule fragment (Fig. 1a), to generate a functional
mimetic,30 i.e. a mimic that reproduces binding, but may not
necessarily mimic structure. As a screening approach, this
offers the advantage of exploiting a peptide with intrinsic target
affinity as an anchor to permit identication of weakly binding
fragments. A related principle has been exploited in the
REPLACE strategy whereby – aided by in silico methods – key
residues of known peptide ligands were “mutated” for molec-
ular fragments to identify inhibitors of conventional drug
discovery targets e.g. kinases.31–35 Subsequently, extension of
this concept to a-helix mediated PPIs has been achieved by
screening peptide-small molecule hybrids in silico, then
preparing promising candidates for experimental validation
using click chemistry.36–38 In this work, we instead use reversible
hydrazone formation39 between peptide hydrazones and an
aldehyde library together with dynamic ligation screening40,41 to
identify peptide-fragment hybrids. Such dynamic, template
assisted methods shi thermodynamic equilibria in favour of
the highest affinity ligands40–44 and can target unoccupied
binding sites45 in an unbiased manner; they have proven
successful for discovery of active site inhibitors,46–49 but not
been applied to PPI inhibitor discovery.
As a model b-strand mediated PPI, we use the GKAP/SHANK-
PDZ50 which, plays a role in the organization of synaptic protein
complexes and has been linked to several neuronal disorders.51
There are >250 PDZ domains with several therapeutically rele-
vant proteins known to exhibit their function through a PDZ
mediated interaction.52–54 Ligand discovery for PDZ domains
has proven challenging (e.g. fragment-based screening was
unsuccessful for the PDZ domain of PSD-95 55), with the
majority of potent ligands based on protein,56,57 peptide58,59 or
peptidomimetic scaffolds27,60–62 and limited examples of small-
molecules.63–66 This rendered the GKAP/SHANK-PDZ interaction
as a stringent test for our dynamic ligation screening approach.
Using a three-residue sequence from the GKAP ligand, C- and N-Chem. Sci.terminal hydrazones were generated, then peptide-fragment
hybrid assembly under neutral conditions performed in the
presence of protein as a template and directly coupled to
a uorescence-based biophysical assay (Fig. 1b). Characteriza-
tion of the most promising hits using ITC, NMR, X-ray crystal-
lography and molecular dynamics simulations established the
hits as selective SHANK1 PDZ ligands (in comparison to PSD-95)
with comparable potency to the GKAP PDZ-binding motif (PBM)
(Ac-EAQTRL-COOH) from which they were derived. Potency was
achieved by binding to a cluster of basic residues proximal to
the peptide binding site on the PDZ domain. These results
thus establish dynamic ligation screening as a powerful tool
to identify b-strand peptide-fragment mimetics as PPI inhibi-
tors and broaden the scope of design strategies for PPI inhibitor
discovery.Results and discussion
Hybrid library design
We chose acylhydrazone bond formation to covalently link
fragments to peptide anchors (Fig. 2a). In the presence of
anilines, the reaction can be performed close to neutral pH,
allowing the screening to take place close to a physiologically
relevant pH and temperature with the protein as a template for
product formation.67,68 Moreover, at neutral pH acylhydrazones
are stable, facilitating subsequent hit validation.69,70 Given the
commercial availability of a large array of aldehydes, we thus
designed the hybrids to be formed from peptide hydrazides.
Peptide anchors were designed based on the key features of
the interaction between the wild type GKAP sequence and
SHANK1 PDZ.50 Class I PDZ domains bind to consensus
sequences with a Thr/Ser in the -2 position from the C-terminus,amino acids and the fragment-targeting binding site.
© 2021 The Author(s). Published by the Royal Society of Chemistry
























































































View Article Onlinewith the C-terminus hydrophobic residue and free carboxylate
being the main determinants of affinity.71,72 The plasticity of
PDZ domains allows the accommodation of various hydro-
phobic side-chains at the C terminus of the peptide,73 which we
hypothesized to be an ideal target site for hydrophobic frag-
ments; for SHANK1, Leu dominates for C-terminal carboxylates
and Phe for non-C-terminal sequences.74 This led to compounds
1 and 2 (Fig. 2b and Scheme S1†), directing the fragments
toward the C-terminal hydrophobic pocket on SHANK1 PDZ. On
the other hand, compounds 3 and 4 contained the TRL-COOH
core sequence and the hydrazide functionality was attached to
the N-terminus of the peptide through a 2 or 3 carbon atom
linker (Fig. 2c and Scheme S2†), allowing exploration of the
protein surface for secondary binding sites further away from
the key residues. To ease purication, all peptide hydrazides
were reacted with benzaldehyde, yielding the corresponding
acylhydrazones (1-, 2-, 3-, 4-A001).
A diversity-based selection was performed on commercially
available aldehyde fragments obeying guidelines for fragment-
based drug design,75 resulting in a small library of 129
compounds (A001–A129, Table S1 and Fig. S1†). AcylhydrazoneFig. 3 Results of the fluorescence anisotropy competition screening for
using the diverse screening library (A001-A129). (b) FA competition curve
including near neighbors (A130-165) for the initial hits. (d) FA competi
validation assays were performed in 50 mM NH4Ac buffer, pH 6.5, 10 m
TRL-COOH as tracer at room temperature. Compounds 1-, 2-, 3-, 4-A0
presence of SHANK1 PDZ for 24 hours. Anisotropy is expressed relative to
were defined based on the relative anisotropy of the (i) buffer control (rb
thresholds are coloured blue and red respectively. Labels indicate the two
values and FA validation for additional hits, see ESI Fig. S5–S12.† (e) Struct
enantiomeric purity of fragment A161 is unknown.
© 2021 The Author(s). Published by the Royal Society of Chemistryformation was tested in the presence of 10 mM aniline67 at pH
6.5 using a 5-fold excess of the competing aldehydes, which
revealed fast and complete exchange of the benzaldehyde motif
(Fig. S2†), reaching equilibrium within 24 hours. To allow us to
perform the hybrid formation and screening in the presence of
the target protein in a single step, it was necessary to rst
establish that SHANK1 PDZ was still able to bind to its natural
ligand under the same conditions. For this, FITC labelled GKAP
was used and the uorescence anisotropy measurements gave
an initial KD of 1 mM, which did not signicantly change over
the course of 24 hours (Fig. S3†).Library screening
Prior to screening, the intrinsic inhibitory potency of the
peptide hydrazones 1-, 2-, 3-, 4-A001 was determined (Fig. S4†);
they were no more active than the parent peptides. Then, hybrid
formation and screening were performed by mixing each of
these compounds at 10 or 50 mM concentration with 5 equiva-
lents of the aldehydes in a 384 well microtiter plate. Aer 24
hours of equilibration in the presence of SHANK1 PDZ protein,
FITC-Ahx-TRL-OH was added as competitor. In all assays, thecompounds 1–4. (a) Screening results for hydrazones formed from 1–4
s of the best hybrid hits. (c) Screening results using the extended library
tion curves for hybrids from the extended screen. All screening and
M aniline using 1 mM final protein concentration and 10 nM FITC-Ahx-
01 were incubated individually with 5 equivalents of fragments in the
the control experiment where no competitor is present. Hit thresholds
uffer  3s) and (ii) the TRL control (rTRL  3s). Compounds below these
best aldehyde fragment hits from the individual screens. For individual
ures of the synthesized hit compounds. The absolute configuration and
Chem. Sci.
Fig. 4 Hit validation by ITC. Fitted thermograms and thermodynamic
signatures for the tested peptides and hydrazones. ITC data were
























































































View Article OnlineGKAP PBM sequence (Ac-EAQTRL-COOH), Ac-TRL-OH and
a buffer control were used, which facilitated determination of
threshold values for the hit compounds (Fig. 3a, S5 and S6†).
Any hybrid that exceeded the activity of its parent compound
was considered an improvement caused by the replacement of
the fragment.
The two different truncation strategies had profoundly
different hit rates, reecting the affinity of the parent
compounds. The removal of the key C terminal residue of GKAP
did not result in detectable binding affinity for the parent
compounds 1-A001 and 2-A001 (Fig. S4†); our hypothesis was
that a hybrid with a fragment effectively mimicking the trun-
cated sequence could result in detectable affinity. Our library
did not contain such fragments; hit rates were low, perhaps
reecting the challenge in attaining the correct orientation and
composition of functionality needed to faithfully mimic the key
interactions afforded by the natural truncated sequence. The
solitary conrmed hit (Fig. S7†) appeared to interfere with the
assay and was not considered further.
Conversely, using compounds 3-A001 and 4-A001 with
intrinsic potency (Fig. S4†) resulted in a higher hit rate (Fig. 3a,
S5 and S6†), with 51 hybrids exceeding the activity of Ac-TRL-
COOH, which was the core motif in both hybrid sequences.
The most promising hits were re-tested in order to validate the
screening assay (Fig. 3b, S8 and S9†). The IC50 values measured
for the best hits were in the range of 5–6 mM, a 10-fold
improvement compared to the parent Ac-TRL-COOH sequence,
indicating that covalent attachment of the fragment contributes
favourably to interaction with the protein. Interestingly, the
most potent hybrids formed from 3 and 4 contained the same
carboxylic acid functionalized aromatic aldehyde fragments
(A047 and A048, Fig. 3b), indicating that these types of frag-
ments might play an important role in binding.
Based on this observation, we extended the aldehyde library
to near neighbours of these fragments and selected an addi-
tional 36 carboxylic acid functionalized aromatic aldehydes
(A130-165, Fig. S1 and Table S1†) with which to carry out
a further screen. In this extended screen, the hit rate increased
signicantly (Fig. 3c, d and S10–S12†), conrming that an acidic
binding motif is generic for favourable binding and conrming
they could not have been identied without conjugation to the
anchor peptides.
In the subsequent validation, the IC50 values of the best hits
(formed from compound 4 and A144 or A161) reached or
slightly exceeded the binding affinity of full length GKAP
peptide, indicating that the fragment can restore the affinity of
the truncated sequence to that of the wild-type peptide. Signif-
icantly, all but one of the aldehyde fragments showed no
inhibitory capability on their own in the assay (Fig. S13†).acquired in 25 mM Tris, pH 7.5 buffer containing 150mMNaCl at 25 C
by injecting 0.75–1 mM peptide or hydrazone solution into 75–150 mM
protein in the cell. For individual raw ITC data and fitted thermograms
see Fig. S14.†Structure–activity relationships
To establish structure–activity relationships, the most active
hybrids were synthesized individually (Fig. 3e and Scheme S2†)
and subjected to further characterization by isothermal titra-
tion calorimetry (ITC) (see Fig. S14†). The truncation of the
GKAP sequence (KD ¼ 2 0.3 mM) to its core TRL motif (KD ¼ 22Chem. Sci. 3 mM) resulted in a decrease in affinity (Fig. 4 and Table 1).
This was accompanied by the loss of binding enthalpy but also
resulted in a more favourable entropy of binding (Table 1),© 2021 The Author(s). Published by the Royal Society of Chemistry
Table 1 Thermodynamic parameters for the tested compounds
binding to SHANK1 PDZ derived from the ITC experiments




GKAP 1.07  0.01 2.0  0.3 29.6  0.4 9.7
TRL 1.04  0.02 23  2 19.3  0.5 24.1
3-A001 1.04  0.04 16  3 9.7  0.6 59.0
4-A001 1.00  0.03 14.8  0.8 20.9  0.2 22.2
3-A047 0.94  0.01 8  1 11.5  0.4 59.1
4-A047 1.06  0.01 4.6  0.2 17.1  0.1 44.8
3-A048 1.03  0.01 10  1 14.1  0.3 48.4
4-A048 0.99  0.01 3.1  0.2 22.3  0.2 30.7
3-A144 1.00  0.02 7.1  0.9 14.4  0.2 50.1
4-A144 1.03  0.01 3.1  0.2 18.3  0.1 44.1
3-A161 0.84  0.01 4.8  0.4 18.0  0.3 41.3
4-A161 1.00  0.00 1.54  0.05 28.0  0.1 17.3
























































































View Article Onlinepresumably due to the loss of rotatable bonds on amino acid
removal. Hydrazones formed from benzaldehyde and this core
motif (compounds 3-A001 and 4-A001) revealed slightly
increased affinity compared to the TRL motif (Fig. 4 and Table
1), which might be the result of favourable interaction of the
aromatic fragment or the hydrazone bond itself with the
protein. Hybrid hits in which the fragments contained the
additional carboxylic acid functional group resulted in
increased binding affinity in every case (Fig. 4 and Table 1),
which conrmed the importance of the acidic group and that
these fragments actively contribute to SHANK1 binding. Inter-
estingly, hybrids with the C3 linker (compound 4 hydrazones)
showed more favourable enthalpic contributions and slightly
higher affinity in comparison to compounds having the C2
linker (compound 3) when the same fragment was attached.
This indicated that the more exible linker allows for a better
orientation of the fragment leading to a more favourable
enthalpy of binding, but also increases the entropic cost of
binding, leading only to a moderate difference in the overall
binding energy.
Based on its affinity and the thermodynamic signature,
compound 4-161 was identied as the best mimic of the wild-
type sequence. It should be noted that the fragment in this
hybrid has unknown enantiomeric purity, therefore the binding
affinity might be the average of the two diastereoisomers. To
compare the effect of fragments on binding energy we calcu-
lated group efficiency values (GE) (Tables S2–S4†). These data
illustrate the potential of the dynamic ligation approach to
rapidly explore structure affinity relationships to identify the
efficient fragments. Moreover, the replacement of the N
terminal EAQ amino acids of GKAP to completely non-peptidic
motifs resulted in similar GE values indicating this strategy can
also provide molecules that are less peptidic in nature, while
keeping the original potency of the native ligand. It is worth
noting that although compound 4-161 possessed the highest
binding affinity, the aldehyde fragment in compounds 4-A048
or 4-A144 have slightly higher group efficiencies (Tables S2–S4†)
and may therefore represent equally reasonable starting points
for further optimization.© 2021 The Author(s). Published by the Royal Society of ChemistryTo obtain more insight on the molecular nature of the
interaction between the peptide-fragment hybrids and SHANK1
PDZ, co-crystal structures were solved for compounds 3-A047, 4-
A047, 3-A048, and 4-A048 with SHANK1 PDZ at resolutions of
1.5–2.2 A (Table S5†). In all structures, hybrids bound to the
anticipated binding site with a similar conformation to the wild
type sequence within the core amino acid sequence (RMSD
values between 0.18–0.32, Fig. S15–S19 and Table S6†), indi-
cating that the peptide component of the hybrid indeed fulls
the role of an anchor directing fragments towards the protein
surface. In all hybrids, the hydrazone bond existed in an E
conguration with the aromatic ring of the fragment co-planar
with the hydrazone. The N terminal glutamate of the wild-type
GKAP interacts with R679, thus we anticipated that the
carboxylate of the hybrids might reproduce this same interac-
tion. However, the N terminal part of the hybrids showed
different binding behaviour in comparison with the wild type
sequence. In some cases, we observed multiple conformations
of the same compound having different orientations of the
fragments relative to the peptide component presumably
allowed by the conformational exibility of the linker region.
The more favourable entropy of binding (Table 1) supports the
hypothesis that linker exibility leads to a “fuzzier” mode76 of
interaction (see below) although the carboxylate exhibited
a slight preference for interaction with R736 (Fig. S19†) which
differs from the wild-type GKAP peptide (see above) and likely
arises from a combination of hybrid exibility and the
propensity of R736 to engage in effective charge-reinforced
hydrogen-bonding interactions.
It is noteworthy that the linker exibility resulted in high B-
factors with some missing density around the fragment in most
of the structures. Although this leads to slight uncertainty about
the exact location of the fragments, we hypothesize that the key
carboxylic acid moiety moves dynamically across a positively
charged patch formed by R679, R736 and R743 on the protein
surface (Fig. 5), making transient charge-reinforced hydrogen-
bonding and cation–p interactions which is also consistent
with a more favourable entropy of interaction. Finally, in the
crystal structures where strong electron density allowed deter-
mination of the location of the fragment, we observed that this
motif interacted with a loop of a symmetry related protein in the
crystals (Fig. S17 and S18†). To probe this behaviour further, we
determined the rotational correlation time (sc) of the SHANK1
PDZ protein in the absence/presence of ligand using NMR T1
and T2 relaxation experiments (Fig. S20†). These analyses indi-
cated similar sc values for apo-SHANK1 and SHANK1 in the
presence of these compounds, meaning that the interaction in
the X-ray structure most likely arises from a crystal packing
specic interaction.
To provide support for the hypothesis that the hybrids target
the cationic patch on the surface of SHANK1, we performed
molecular dynamics simulations on the SHANK1-compound 3-
A048 complex using the crystal structure as a starting point.
Over the course of three repeats of 200 ns, the aromatic
carboxylate of the fragment indeed moves across the surface of
the SHANK1 protein, making transient contacts with R679,
R736 and R743, as well as intramolecular interaction onto theChem. Sci.
Fig. 5 Superimposed crystal structure of 3-A047 (cyan, PDB: 6YWZ),
4-A047 (blue, PDB: 6YX1), 3-A048 (yellow, PDB: 6YX0) and 4-A048
(orange, PDB: 6YX2) in complex with SHANK1 PDZ (green) showing
two different orientations of the complexes. The core TRL sequence
binds in a similar manner to the native wild-type ligand in both crys-
tallographic protomers whilst the orientation of the acylhydrazone
fragment component varies for each ligand and appears to switch
interactions dynamically with a series of basic residues (R679, R736,
R743) at the periphery of the b-strand binding cleft on the PDZ
domain.
























































































View Article Onlinearginine in the peptide ligand to a lesser extent (see: ESI, Movie
S1†). The distance between the carboxylate and these residues
plotted against time over the course of the simulations
(Fig. S21†) further indicates that the aromatic carboxylate is
able to make transient non-covalent contacts in turn with each
of the positively charged side-chains of the three arginine resi-
dues with a preference for R736.
Since Class I PDZ domains bind to consensus sequences,71,72
we set out to further assess the selectivity of the peptide-
fragment hybrids against another Class I PDZ domain. We
compared the ability to bind to SHANK1 PDZ against the ability
to bind to the PDZ domain of PSD-95, a therapeutically impor-
tant target in neuronal diseases and cancer.58 Wemonitored the
binding using chemical shi perturbations in the 1H–15N HSQC
spectra of the PDZ domain of PSD-95 (Fig. S22, S23, Tables S7
and S8†). These analyses indicated weak binding with EC50 ¼
2.4  0.3 mM for 4-A047 (Fig. S24†), which is comparable with
the affinity of GKAP towards PSD-95 (Table S7†). The observed
weak potency of GKAP and the peptide-acylhydrazone fragment
hybrids towards PSD-95 likely derives from its preference for Val
or Ile at the C-terminus of its ligands.77 However, PSD-95 alsoChem. Sci.lacks the patch of cationic residues proximal to the C-terminal
carboxylate binding site. Such a result provides condence that
the dynamic ligation screening approach used here can encode
and retain selectivity.
Conclusions
The identication of inhibitors of b-sheet mediated PPI inter-
faces, which are generally shallow and elongated, is chal-
lenging. Here, we used dynamic ligation screening to identify
peptide-fragment hybrids linked through an acylhydrazone
bond, that are able to functionally mimic a b-strand and inhibit
its PPI using GKAP/SHANK1 PDZ as a model interaction. The
identied ligands were shown to bind with comparable potency
to the GKAP PBM (Ac-EAQTRL-COOH) ligand from which they
were derived and were selective when tested against an alter-
native PDZ domain. Crystallographic studies supported by
molecular dynamics analyses indicated that the fragment
portion of the hybrids was able to reinforce SHANK1 recogni-
tion by engaging in transient charge-reinforced and cation–p
interactions on the protein surface. The observation of this
distinct binding mode provides new insight on the molecular
recognition of SHANK1 towards its peptide/protein ligands that
can inform chemical probes development – a focus of our future
studies.
More generally, our approach is advantageous in that it
allows: (i) use of commercially available aldehyde fragments to
build a small, diverse library then extend it to near neighbors
based on initial hits; (ii) ligation to be performed under
conditions where the reaction is reversible, and is compatible
with the screening assay; (iii) validate hits easily without the
need for a further synthetic step, thus providing useful insights
on structure–activity relationships; and (iv) explore unoccupied
binding sites on a protein surface in an unbiased manner to
generate ligands with target affinity and selectivity. Signi-
cantly, whilst conventional fragment based approaches and
reversible protein-directed fragment discovery in the form of
disulde-tethering have been used to develop modulators of
PPIs,78–80 the use of ligand-directed fragment discovery to
develop modulators of PPIs has not been widely developed.
Thus, these proof-of concept results exemplied here point to
future application of dynamic-ligation screening to identify and
optimize PPI modulators more broadly.
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